Marinus Pharmaceuticals, Inc.
$45 Million - Follow-OnJoint Bookrunner
$30 Million - Follow-OnJoint Bookrunner
$151 Million - Initial Public OfferingJoint Bookrunner
ADMS / Using Drug Delivery Tech to Make Better Drugs; Initiating ADMS with OP
CLL Survey Suggests Significant Opp for Next-Gen BTKs to Improve on Imbruvica
JNJ / Leadership Series: Growth Acceleration with Strong FCF Generation